One-quarter of Class 1 innovative drugs come from Shanghai. Detailed explanation of the "code" for the development of Shanghai's pharmaceutical industry

Zhang Jiang·China Pharmaceutical Valley Biomedical Innovation Exchange Center Zheng Yingying, China News Online, October 5th (Reporter Zheng Yingying) "This year Shanghai has approved 6 Class 1 innovative drugs, a record high, accounting for about a quarter of the national total.
One," Zhang Qing, deputy director of the Shanghai Municipal Drug Administration, said recently
.
The biomedical industry is one of the three leading industries in Shanghai
.
Data show that in 2020, the scale of Shanghai's biomedical industry will exceed 600 billion yuan (RMB, the same below), of which the total output value of related industries will exceed 140 billion yuan
.
Why can Shanghai become China's biomedicine research and development highland and industry hotspot? There are the following "passwords": Research and development of the exhibition "Check in with a bag" In recent years, the scale of Shanghai's biomedical industry has continued to maintain a rapid growth trend, with a sound industrial system, a high degree of internationalization, and the country's leading R&D and innovation capabilities
.
Wu Jincheng, director of the Shanghai Municipal Commission of Economy and Information Technology, revealed that in the first half of this year, the scale of Shanghai's biomedical industry exceeded 350 billion yuan, a year-on-year increase of 22.
8%
.
He said that Shanghai strives to achieve the city's biopharmaceutical industry scale of 1.
2 trillion yuan by 2025, to achieve a batch of key and core technologies that can be independently controlled, so that a batch of innovative results can achieve remarkable results
.
"We can now say that we can achieve'land and other projects' and'building and other projects'
.
Especially in Lingang's "Life Blue Bay" (located in the China (Shanghai) Pilot Free Trade Zone in the new area of ​​the biomedical industry park) , We have provided customized, high-level, standard R&D buildings and standard factories, which can be'carried in', and R&D and production can be carried out when they come
.
" Wu Jincheng said
.
He introduced that the Shanghai biomedical industry is currently focusing on three aspects: The first aspect is core technology research, especially in the fields of innovative drugs, high-end medical devices, high-end preparations, and urgently needed medical supplies for public health.
Break through
.
The second aspect is to strengthen the layout in frontier fields, carry out forward-looking layouts in the fields of antibody drugs, cell therapy, gene therapy, and continue to advance around the fields of brain science, stem cells and regenerative medicine.

.
The third aspect is to strengthen the transformation of innovation achievements
.
Shanghai has formed a "1+5+X" industrial development layout with Zhangjiang as the core, Lingang New Area and other 5 characteristic parks as the support, and other characteristic bases as a supplement, and a joint development pattern of "Zhangjiang R&D + Shanghai Manufacturing" Continuously optimize
.
The supporting policies closely follow Shanghai's "Several Opinions on Promoting the High-Quality Development of the Biopharmaceutical Industry in this Municipality" released this year.
The content covers the policy system of the entire industry chain including R&D, clinical, manufacturing, and application, and it also clarifies the future of Shanghai's biomedical industry.
What will be developed in 3 years? How to develop? How to support? Wu Jincheng said that Shanghai's support for the biomedical industry includes not only financial support for research and development, carrier support for factory buildings, but also streamlining and optimization of service approvals
.
At the same time, Shanghai is also promoting the facilitation of customs clearance for research and development items and special items, establishing a "white list" of biomedicine pilot companies and items to facilitate customs clearance for enterprises
.
In addition, Hu Hongyi, deputy director of the Shanghai Municipal Health Commission, introduced that Shanghai pioneered the release of the "Municipal Hospital Medical-Enterprise Collaborative Research Innovation Platform (HI-CLIP)-Clinical Trial Accelerator" platform, hoping to graft the needs and resources of enterprises and hospitals.
Effectively shorten the average start-up time of clinical trials, "This is also the unique advantage of Shanghai's development of biomedicine.
We need a platform to do "matchmaker" and do grafting, so that doctors and enterprises can quickly connect and interact
.
" Long-term planning shows that both hands At present, 18 and 17 of the world's top 20 pharmaceutical companies and medical device companies have settled in Shanghai, setting up China headquarters, R&D centers or production bases in Shanghai
.
Shanghai has established 6 national-level and 17 municipal-level clinical medical research centers, and has gathered a group of leading domestic research institutes in the fields of life sciences and pharmacy
.
Liu Ping, deputy director of the Shanghai Municipal Commission of Economy and Information Technology, stated that Shanghai is "bringing in" on the one hand, and on the other hand, it actively promotes related enterprises in the city to "go global", including "businesses going to sea", "products going to sea", and "technology going to sea".

.
For example, he said that this epidemic has brought great challenges to the world.
Many biomedical companies in Shanghai have helped the world fight the epidemic, and their new coronavirus detection kits, masks, and smart imaging products have been exported to many countries
.
In order to "add firewood and fire" to the development of Shanghai's biomedical industry, Shanghai will host the first "Shanghai International Biomedical Industry Week" from the 11th to the 14th of this month
.
It is reported that Shanghai will regularly hold this event every year in the future, striving to build another international exchange platform for the biomedical industry
.
(over)